In-Vitro Diagnostics

In-Vitro Diagnostics Market by Component (Data Management Software & Services, Instruments, Reagents & Kits), Technology (Clinical Chemistry, Coagulation & Hemostasis, Hematology), Specimen, Application, End User - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the in-vitro diagnostics market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[190 Pages Report] The In-Vitro Diagnostics Market size was estimated at USD 109.05 billion in 2023 and expected to reach USD 115.04 billion in 2024, at a CAGR 6.11% to reach USD 165.27 billion by 2030.

In-Vitro Diagnostics Market
To learn more about this report, request a free PDF copy

In-vitro diagnostics (IVD) is a critical aspect of the healthcare industry that involves the analysis of biological samples outside of the human body in a laboratory setting. These diagnostic tests play a crucial role in disease prevention, early detection, and targeted therapies by providing valuable information on an individual's health status. IVD encompasses various medical devices, assays, reagents, and analytical instruments to facilitate accurate diagnoses and personalized patient treatment plans. IVD testing is performed on multiple biological specimens, such as blood, urine, saliva, tissue biopsies, or other bodily fluids. The test results aid healthcare professionals in making informed decisions regarding diagnosis, prognosis, therapy selection, and disease management. The increasing global aging population and prevalence of chronic diseases are significant factors contributing to market growth. Rising awareness of early disease detection and the adoption of advanced and automated instruments is expected to increase market adoption. Stringent regulations and guidelines imposed by various health authorities and agencies worldwide and complex reimbursement systems may hamper the market growth. Technological innovations within the IVD industry are transforming the landscape by enabling rapid test results with portable devices that reduce turnaround time while maintaining high levels of accuracy.

In-Vitro Diagnostics Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Component: The integral role of instruments, and reagents in in-vitro diagnostics

Data management software in in-vitro diagnostics is designed to handle and analyze the vast amount of data generated by diagnostic tests. This software helps manage patient information, test results, and laboratory workflow efficiently. Diagnostic instruments are used to conduct tests and analyses on collected biological samples. These instruments include simple manual devices, such as pipettes and centrifuge and complex automated systems that simultaneously perform multiple tests with minimal human intervention. Reagents & kits are crucial consumables used in conjunction with in-vitro diagnostics instruments to perform diagnostic tests. Reagents are chemical substances that react with specific sample components to produce measurable signals or detect analytes of interest. In addition to software and consumables, services include maintenance and support for diagnostic equipment, training programs for laboratory personnel, consulting on regulatory compliance, quality management systems, and assistance with test method validation.

Application: Revolutionizing application of in-vitro diagnostic in cancer care

In-vitro diagnostics (IVD) plays a critical role in diagnosing autoimmune diseases to enable effective treatment strategies. In-vitro diagnostics technologies such as enzyme-linked immunosorbent assays (ELISA) and immunofluorescence tests are increasingly used for identifying autoantibodies specific to these conditions. Cardiology IVD tests aid in the diagnosis and risk assessment of cardiovascular diseases (CVD), including heart attacks, heart failure, and hypertension, that help in measuring cardiac biomarkers, including troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP) to identify cardiac injury and monitor heart health. IVD plays a vital role in diabetes management by providing accurate and rapid glucose testing solutions. Blood glucose meters, continuous glucose monitoring (CGM) devices, and HbA1c tests are essential IVD tools in diabetes care. In nephrology, IVD tests are employed for detecting and monitoring kidney diseases, electrolyte imbalances, and kidney function, which includes Common tests such as serum creatinine, blood urea nitrogen (BUN), and urine protein measurements. Advancements in IVD technologies, including liquid biopsies and next-generation sequencing (NGS), are transforming cancer diagnostics by offering minimally invasive testing options that support early detection, personalized therapies, and monitoring treatment response.

Regional Insights

The Americas has a significant landscape in the in-vitro diagnostic market owing to the presence of key manufacturers that develop instruments and accessories with strong product lines distinguished by reliable performance and competitive pricing. The region's advanced healthcare infrastructure, high healthcare spending, and favorable reimbursement policies contribute to the widespread adoption of IVD technologies. In Europe, market players are conducting R&D activities to offer more comprehensive solutions, including multiple platforms and formats such as instrumentation, software, and consumables for quality control. Strategies adopted by providers in the EMEA region include partnerships with local distributors and acquisitions of smaller IVD companies to expand their geographical presence. The Asia-Pacific region observed a rapidly growing market for IVD, driven by factors, such as a growing population base, increasing healthcare expenditure, and a rising prevalence of chronic and infectious diseases.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the In-Vitro Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the In-Vitro Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Biocare Medical's Advanced Antigen Retrieval Chamber (ARC), Revolutionizing Immunohistochemistry

    Biocare Medical is enhancing accuracy in the immunohistochemistry sector with their latest innovation, the Antigen Retrieval Chamber (ARC). This sophisticated device is designed to foster precision in Heat-Induced Epitope Retrieval (HIER), vital for consistent immunohistochemistry (IHC) and in situ hybridization (ISH) staining results. ARC's capability to adjust temperature between 60 - 121°C and accommodate up to 72 standard or 27 double wide slides makes it versatile for clinical, research, and prion studies. [Published On: 2023-11-15]

  • GenWorks Health launches IVD tests for dengue & malaria

    GenWorks, has introduced a comprehensive series of in-vitro diagnostic tests. These tests include rapid card test kits for detecting dengue and malaria. These meticulously designed tests play a crucial role in combating seasonal epidemics by facilitating prevention, accurate diagnosis, effective treatment, and eventual cure of these diseases. The iScreen Malaria Card Antigen (Pf/Pv) is a visually intuitive lateral flow immunoassay that accurately identifies P. falciparum and P. Vivax in human whole blood. [Published On: 2023-07-27]

  • Oxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics

    Oxford Nanopore and bioMérieux have formed a partnership to explore selected opportunities for introducing nanopore sequencing into the infectious disease diagnostics market. The companies are collaboratively investigating specific opportunities to enhance patient care through the provision of nanopore-based solutions for clinical research and in-vitro diagnostics (IVD). This can enables the company to rapidly and cost-effectively generate specific DNA or RNA sequence data. [Published On: 2023-04-14]

Key Company Profiles

The report delves into recent significant developments in the In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, Adaptive Biotechnologies Corp, Agilent Technologies Inc., Arkray Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biomérieux SA, Danaher Corporation, DiaSorin S.p.A., EKF GmbH, F. Hoffmann-La Roche Ltd., Grifols SA, Hologic, Inc., Illumina, Inc., Menarini Diagnostics, Mindray Medical International Limited, Myriad Genetics, Inc., Ortho-Clinical Diagnostics, Inc., Qiagen GmbH, Randox Laboratories, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Data Management Software & Services
    • Instruments
    • Reagents & Kits
  • Technology
    • Clinical Chemistry
      • Basic Metabolic Panel
      • Electrolyte Panel
      • Lipid Profile
      • Liver Panel
      • Renal Profile
      • Specialty Chemical Tests
      • Thyroid Function Panel
    • Coagulation & Hemostasis
    • Hematology
    • Immunochemistry
      • Enzyme-Linked Immunosorbent Assay
        • Chemiluminescence Immunoassays
        • Colorimetric Immunoassays
        • Fluorescence Immunoassays
      • Enzyme-Linked Immunospot Assays
      • Radioimmunoassay
      • Rapid Test
      • Western Blotting
    • Microbiology
    • Molecular Diagnostics
      • DNA Sequencing & Next-Generation Sequencing
      • Hybridization
      • Isothermal Nucleic Acid Amplification Technology
      • Microarray
      • Polymerase Chain Reaction
    • Urinalysis
  • Specimen
    • Blood, Serum & Plasma
    • Saliva
    • Urine
  • Application
    • Autoimmune Diseases
    • Cardiology
    • Diabetes
    • Drug Testing
    • HIV/Aids
    • Infectious Diseases
    • Nephrology
    • Oncology
  • End User
    • Hospitals & Care Providers
    • Laboratories
    • Patient Self-Testing

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the In-Vitro Diagnostics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the In-Vitro Diagnostics Market?
  3. What are the technology trends and regulatory frameworks in the In-Vitro Diagnostics Market?
  4. What is the market share of the leading vendors in the In-Vitro Diagnostics Market?
  5. Which modes and strategic moves are suitable for entering the In-Vitro Diagnostics Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. In-Vitro Diagnostics Market, by Component
  7. In-Vitro Diagnostics Market, by Technology
  8. In-Vitro Diagnostics Market, by Specimen
  9. In-Vitro Diagnostics Market, by Application
  10. In-Vitro Diagnostics Market, by End User
  11. Americas In-Vitro Diagnostics Market
  12. Asia-Pacific In-Vitro Diagnostics Market
  13. Europe, Middle East & Africa In-Vitro Diagnostics Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 860]
  18. List of Companies Mentioned [Total: 24]
Personalized Medicine Is The Future, And In-Vitro Diagnostics Is Leading The Way
September 25, 2023
Personalized Medicine Is The Future, And In-Vitro Diagnostics Is Leading The Way
The medical industry is changing, and personalized medicine is the future. No longer are we prescribing a one-size-fits-all approach based on averages and generalizations. Instead, we're focusing on each individual patient and their specific needs. To do this, medical professionals are using numerous cutting-edge tools and technologies, such as companion diagnostics, to create targeted treatment plans that give patients the best possible outcomes. In this blog post, we'll take a closer look at in vitro diagnostics and how it's leading the way in personalized medicine.

What Is In Vitro Diagnostics (IVD)?

In vitro diagnostics is a form of medical testing that's performed on samples of blood, tissue, or other bodily fluids to diagnose diseases and conditions. The IVD industry has a broad range of fields, including microbiology, chemistry, hematology, and immunology. The goal of IVD testing is to provide clinicians with accurate and timely results that can help with diagnosis, patient monitoring, and treatment decisions. In-vitro diagnostics play a vital role in personalized medicine, as it allows doctors to identify specific biomarkers and genetic variants that can be targeted with tailored therapies.

How Does Companion Diagnostics Fit Into This Picture?

Companion diagnostics are a crucial component of personalized medicine and are often used in combination with targeted therapies. They're diagnostic tests that are developed alongside a new medication to identify the specific patients who would benefit from the treatment and who would be more likely to experience side effects. By conducting companion diagnostic tests, clinicians can tailor the medication based on the patient's unique genetic makeup, resulting in more effective and personalized treatment plans. This approach is becoming increasingly popular, and the IVD industry is at the forefront of companion diagnostics development.

The COVID-19 Pandemic And The IVD Industry:

The COVID-19 pandemic had a significant impact on the IVD industry, with an increased demand for test kits and reagents. With the emergence of new COVID-19 variants, the need for fast and accurate testing was never more critical. The IVD industry stepped up to the challenge, with numerous companies developing and distributing COVID-19 diagnostic tests worldwide. Furthermore, with the increasing need for telehealth services during the pandemic, the IVD industry responded with the development of remote monitoring devices, enabling patients to take diagnostic tests at home, improving convenience and patient management.

Personalized medicine is the future, and the IVD industry is leading the way with its advancements in companion diagnostics and targeted therapies. The future outlook for the IVD industry is exceptionally positive, with the increasing focus on personalized medicine, the demand for early diagnosis of diseases, and technological advancements in diagnostic devices. With the challenges of COVID-19, the IVD industry has demonstrated its agility and innovation, developing fast and accurate diagnostic tests and telehealth solutions. It's an exciting time for the IVD industry, and we can't wait to see what the future holds.

Frequently Asked Questions
  1. How big is the In-Vitro Diagnostics Market?
    Ans. The Global In-Vitro Diagnostics Market size was estimated at USD 109.05 billion in 2023 and expected to reach USD 115.04 billion in 2024.
  2. What is the In-Vitro Diagnostics Market growth?
    Ans. The Global In-Vitro Diagnostics Market to grow USD 165.27 billion by 2030, at a CAGR of 6.11%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.